PMID- 8566583
OWN - NLM
STAT- MEDLINE
DCOM- 19960304
LR  - 20220225
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 110
IP  - 2
DP  - 1996 Feb
TI  - High levels of transforming growth factor beta 1 in patients with colorectal 
      cancer: association with disease progression.
PG  - 375-82
AB  - BACKGROUND & AIMS: Contribution of transforming growth factor beta 1 (TGF-beta 1) 
      to tumor progression has been suggested. However, little is known about the role 
      of TGF-beta 1 in colorectal cancer. Plasma TGF-beta 1 levels and its expression 
      were analyzed in patients with colorectal cancer. METHODS: Plasma TGF-beta 1 
      levels were measured in 22 patients with colorectal cancer using a TGF-beta 1 
      enzyme-linked immunosorbent assay. Expression of TGF-beta 1 messenger RNA and 
      immunohistochemical distribution of the protein in colorectal cancer tissues were 
      examined. RESULTS: Plasma TGF-beta 1 levels in patients with colorectal cancer 
      (14.8 +/- 8.4 ng/mL) were significantly higher than in normal controls (1.9 +/- 
      1.4; n = 22) (P < 0.001). After curative surgical resection, plasma TGF-beta 1 
      levels decreased in examined patients from 11.9 +/- 6.7 to 3.8 +/- 1.2 ng/mL (P < 
      0.01). TGF-beta 1 messenger RNA was about 2 1/2 times more abundant in colorectal 
      cancer tissues than in control (P < 0.01). TGF-beta 1 was detected in the 
      cytoplasm of colorectal cancer cells immunohistochemically. Both TGF-beta 1 
      messenger RNA expression in colorectal adenocarcinoma tissues and its plasma 
      levels were associated with tumor stage of Dukes' classification (P < 0.05). 
      CONCLUSIONS: These results suggest that plasma TGF-beta 1 levels may reflect 
      overexpression of the gene in colon cancer tissues and are associated with 
      disease progression.
FAU - Tsushima, H
AU  - Tsushima H
AD  - Second Department of Internal Medicine, Osaka University Medical School, Japan.
FAU - Kawata, S
AU  - Kawata S
FAU - Tamura, S
AU  - Tamura S
FAU - Ito, N
AU  - Ito N
FAU - Shirai, Y
AU  - Shirai Y
FAU - Kiso, S
AU  - Kiso S
FAU - Imai, Y
AU  - Imai Y
FAU - Shimomukai, H
AU  - Shimomukai H
FAU - Nomura, Y
AU  - Nomura Y
FAU - Matsuda, Y
AU  - Matsuda Y
FAU - Matsuzawa, Y
AU  - Matsuzawa Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transforming Growth Factor beta)
SB  - IM
MH  - Adenocarcinoma/blood/metabolism/pathology
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/blood/genetics/metabolism
MH  - Blotting, Northern
MH  - Colorectal Neoplasms/blood/*metabolism/pathology
MH  - Cytoplasm/metabolism
MH  - Disease Progression
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - RNA, Messenger/metabolism
MH  - Transforming Growth Factor beta/blood/genetics/*metabolism
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
AID - S0016508596000674 [pii]
AID - 10.1053/gast.1996.v110.pm8566583 [doi]
PST - ppublish
SO  - Gastroenterology. 1996 Feb;110(2):375-82. doi: 10.1053/gast.1996.v110.pm8566583.